Cite
HARVARD Citation
Petrylak, D. et al. (n.d.). 2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer. European journal of cancer. pp. S483-. [Online].